| Name | Title | Contact Details |
|---|---|---|
Jose Carmona |
Chief Financial Officer | Profile |
Theo Proukou |
Senior Vice President and Chief People Officer | Profile |
Jill Murray |
Director, Human Resource Business Partner and Interim Head of Total Rewards | Profile |
Torben Nissen |
Chief Executive Officer | Profile |
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Puerto Rico Labor and Human Resources is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.